Physician profile
George William Gray
NPI 1952494015
$10,599.24
in general payments reported to CMS, 2019-2025
41 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,574 · 2020: $1,260 · 2021: $2,088 · 2022: $2,025 · 2023: $1,775 · 2024: $1,245 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631 · Education: $21.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.83 |
| Education | $21.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,206.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $988.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $931.06 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $899.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $864.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Esperion Therapeutics, INC. | $496.59 | 2020-2023 | Nexletol |
| Pfizer INC. | $457.86 | 2019-2023 | |
| Amgen INC. | $444.06 | 2019-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $392.29 | 2019-2025 | Myrbetriq, Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $383.12 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $365.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $308.85 | 2019-2025 | Breztri, Farxiga |
| Amarin Pharma, INC. | $266.83 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $247.29 | 2019-2023 | Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $192.15 | 2019-2023 | Trintellix |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.